Resistin Signaling Pathway Assay (CAT#: STEM-MB-0376-WXH)

The adipokine Resistin exhibits pro-inflammatory, pro-angiogenic and metastatic properties. resistin signaling pathway promotes VEGF-A expression in human osteosarcoma cells and activates extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 signaling pathways, while ERK, JNK and p38 inhibitors or their small interfering RNA (siRNA) inhibited Resistin-induced VEGF-A expression, as well as endothelial progenitor cell (EPC) migration and tube formation. In addition, Resistin upregulates VEGF-A expression by enhancing activation of the transcription factor nuclear factor-κB (NF-κB).

Study the regulatory mechanism of resistin signaling pathway in clinical medicine
Research on the influence of various medical viruses on resistin signaling pathway
Study the effects of carcinogenic drugs or carcinogenic therapies on resistin signaling pathway

• Luminex Multiplex Assay
• Enzyme-linked immunosorbent assay (ELISA)
• Flow cytometry (FACS analysis) technology

Detectable targets: GAS, ATG5, ATG10, IPS-1, NFκB, RIG-1, IRF9, ATG12, ATG3, ISGF3, VPS34, TRAF3, AMBRA1, ATG2, ATG7, MSK2, UYRAG, Histone-H3, p38, ATG13, ATG4, PI3K, VPS15, IRF5, RIP1, FIP200, JNK, TBK1, TRAF6, MEK3, TRAF5, ULK, MYD88, Vav, TLR3, p38MAPK, ATG16, PROLC3, Rac1, IRAK1, PKR, SH2, WIPi2, LC3I, TLR4, ISRE, mTOR